Health Condition 1: F122- Cannabis dependence
Conditions
Interventions
Intervention1: Hypotheses
1. Participants receiving rTMS targeting the frontopolar cortex will demonstrate a significant reduction in cannabis craving and frequency of use compared to those receiving
Sponsors
Kaling Institute of Medical Sciences Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of Cannabis Dependence Syndrome as per ICD-10 diagnostic criteria Regular cannabis use on more than equal to20 of the past 30 days, confirmed by self-report and positive urine screening Capacity to understand and provide written informed consent Motivation to reduce or abstain from cannabis use during the study period Patients with BPRS score less than equal to 31.
Exclusion criteria
Exclusion criteria: History of seizure disorder, epilepsy, or significant neurological conditions Presence of metal implants, pacemakers, or any contraindications to rTMS Diagnosis of another substance use disorder (except nicotine or caffeine) within the past 6 months Acute suicidal ideation requiring emergency psychiatric care Pregnant or lactating women (confirmed by urine pregnancy test, if applicable) Presence of intellectual disability or significant cognitive impairment affecting consent or task performance Current participation in another clinical trial involving behavioural or neurostimulation interventions. Severe psychiatric illnesses such as schizophrenia, mania, other mood, and psychotic disorders. Any acute mood disorder or psychotic disorders arising due to substance use. Patient is on mood stabilisers or antipsychotics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcomes 1. Cannabis Craving Measured weekly using the Marijuana Craving Questionnaire 17 (MCQ-17)15. 2. Cannabis Use Assessed via Timeline Follow-Back (TLFB)16 and confirmed with urine THC tests at baseline, Week 2, Week 4, Week 8, and Week 12.Timepoint: Weekly for craving Week 2,4,8 and 12 with urine screening | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Impulse Control & Decision-Making Evaluated using Go/No-Go Task17, Delay Discounting Task, & Barratt Impulsiveness Scale (BIS-11)18. 2. Emotion Regulation Assessed with the DERS questionnaire19. 3. Daily Functioning Measured using the WHO Disability Assessment Schedule (WHODAS 2.0)20. 4. Relapse/Abstinence Defined by self-report & urine testing. 5. Tolerability & Side Effects Monitored after each rTMS session with a symptom checklist.Timepoint: Before intervention & after, followed up in week 2,4,8 & 12. Self report any time by the patient Side effects after every rtms session | — |
Countries
India
Contacts
Public ContactDr Anna Sehgal
Kalinga Institute of Medical Sciences, Bhubaneswar
Outcome results
None listed